The role of endothelial nitric oxide synthase gene polymorphisms in patients with lung cancer. (20th July 2020)

• Record Type: Journal Article
• Authors: Koçer, Canan; Benlier, Necla; Balci, Sibel Oğuzkan; Pehlivan, Sacide; Şanli, Maruf; Nacak, Muradiye
• Is Part Of: Clinical respiratory journal. Volume 14:Number 10(2020)
• Page Start: 948
• Page End: 955
• Publication Date: 2020-07-20
• Subjects: endothelial nitric oxide synthase -- lung cancer -- nitric oxide -- polymorphism; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13228
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Objectives: Lung cancer is a disease characterized by uncontrolled cell growth in the lung tissues. The most common causes of lung cancer include smoking, exposure to radon gas, asbestos, environmental pollutants as well as genetic factors. Nitric oxide (NO) has potential mutagenic and carcinogenic activity and may play an important role in lung cancer. Endothelial NO, synthesized from L‐arginine by endothelial NO synthase (eNOS), inhibits apoptosis and promotes angiogenesis and tumor cell proliferation. The aim of the present study was to examine the possible relationship between eNOS gene intron 4 variable number of tandem repeat (VNTR) and exon 7‐ G894T (Glu298Asp) polymorphisms and lung cancer risk. Methods: DNA was extracted from peripheral blood leukocytes of 107 lung cancer patients and 100 control subjects. Designated polymorphisms were identified by polymerase chain reaction (PCR) and/or restriction fragment length polymorphism (RFLP). Results: Our study showed that the frequencies of the b/b genotype and b allele of eNOS gene intron 4 VNTR polymorphism were significantly higher in lung cancer patients than in controls ( P < 0.05). However, there was no significant association between eNOS gene G894T polymorphism and lung cancer risk ( P > 0.05). Conclusion: These results suggest that the presence of the intron 4 VNTR* b allele and b/b genotype may be a genetic risk factor for development of lung cancer. Further larger‐scale studies are needed to confirm these findings.